Breast cancer in relatives of women with breast cancer

October 25, 2001

N.B. Please note that if you are outside North america the embargo for Lancet press material is 0001 hours UK time Friday 26th October 2001.

Although first-degree relatives of women with breast cancer (mothers, sisters, daughters) are at increased risk of the disease, most women who develop breast cancer do not have an affected relative, report researchers from Oxford in this week's Lancet.

These workers also show that the more affected relatives a woman has, the more likely she is to develop the disease. Understandably, this risk is of concern to both parties. Previous studies have not been sufficiently large accurately to identify the size of the risks.

An analysis published this week in The Lancet combines the results of studies already done and comes up with detailed estimates of the risks of developing breast cancer at various ages. One finding is that the number of affected relatives is more important that the age the relatives were when their cancers were diagnosed.

Members of the international Collaborative Group on Hormonal Factors in Breast Cancer (whose members are listed on The Lancet website www.theLancet.com) combined the results of 52 separate studies, and in total compared the risks of breast cancer in first-degree relatives in 58,209 women with breast cancer with the risks in 101,986 women without breast cancer. They found that the lifetime incidence of breast cancer for women with one affected relative was 7.8%; for women with two affected relatives, 13.3%; and for women with three affected relatives, 21.1%. The risk was the same whether mother or daughter were affected; and that risks were greater in older than in younger women.

The authors of the report firmly put these findings in proportion, "Eight of nine women who develop breast cancer do not have an affected mother, sister, or daughter. Although women who have a history of breast cancer are at increased risk of the disease, most will never develop breast cancer, and those who do will be over 50 when their cancer is diagnosed."
-end-
Contact: Professor Valerie Beral ICRF Cancer Epidemiology Unit, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE, UK; T) +44 (0) 207 269 3141; F) +44 (0) 207 269 3262; E) pressoffice@imperialcancer.co.uk

Lancet

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.